UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
10,800.00-8.00 (-0.07%)
At close: 05:04PM BST
Sign in to post a message.
  • J
    JUDY
    Crypto currency as we all know have been changing lives since many years back, and as a beginner which I am I was very afraid to invest in crypto but however I’ve been reading about it. Few months ago I met Mr Benjamin Richard. who is a professional day trader with his help and signals I made 5 BTC Witt instant successful withdraw. You can reach him via 🆃🅴🅻🅴🅶🆁🅼.
    @ Benjamin_Richard2
  • P
    PassingBye
    So is AZN still going to acquire MREO as well?
  • B
    Barry
    Is AZN still interested in MREO ?
  • P
    Philippe
    Isn’t AZN buying Mereo Pharmaceuticals?
  • r
    rozenboom
    AZN looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
  • V
    VERBOUT
    They just featured AZN on this sites morning watchlist. (http://market-engross.club)
  • C
    CHARLES
    Too many scams out here but I can’t be scared of making money. If its worth the Risk I’m in 💯. I started investing using Jeff Rogers Platform Last Year , he shared his commercial techniques and helped me achieve my goals and now the profit rate is exponential. Contact On. 🆃🅴🅻🅴🅶🆁🅼: (@Jeff_Rogers1) Look Up To Him On Wh@+$@pp +1 (317) 953‑3794
  • C
    Cloggervic
    Analysts estimate the newly proven drugs in the pipeline will raise AZNs bottom line by 17% over the next year making it a screaming buy here.
  • D
    Darrell
    Is AZN working out deal to buy MREO and their pipeline ?
  • A
    Adam
    People are taking profit from AZN and moving it to other stocks that has dropped a lot more. AZN was a safety play in the past year since it hasn’t dropped much at all…. Remember in a recession, all stocks go down eventually as it’s needed to reach a bottom
  • W
    Winorlose
    DEBTS $33 BB, cash $6 BB, wait for $40!
  • D
    Dave
    By Jaime Llinares Taboada


    AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

    The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

    This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

    Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
  • W
    Winorlose
    Time to get lean, not buy a co!!!
    Noooo thanks
  • T
    Terry
    Hey Froehling what did you say
  • I
    Irish
    Good news from ASCO on impact of Inhertu on late stage breast cancer.
  • D
    Diane
    1.85% of institutions would consider $AZN a core holding, constituting over 8% of their portfolio